Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression

J Immunol. 2001 Sep 15;167(6):3164-73. doi: 10.4049/jimmunol.167.6.3164.

Abstract

The NF-kappaB family of transcription factors functions broadly in the host control of immunoregulatory gene expression, inflammation, and apoptosis. Using Jurkat T cells engineered to inducibly express a transdominant repressor of IkappaBalpha, we examined the role of NF-kappaB in the regulation of cytokine and apoptotic gene expression. In this T cell model, as well as in primary T lymphocytes, expression of TNF-related apoptosis-inducing ligand (TRAIL) apoptotic signaling protein was dramatically down-regulated by inhibition of NF-kappaB binding activity. TRAIL acts through membrane death receptors to induce apoptosis of activated T lymphocytes and can be up-regulated by a variety of physiological and pharmacological inducers. However, regulation of TRAIL gene expression has not been defined. Treatment with TCR mimetics (PMA/ionomycin, PHA, and anti-CD3/CD28 Abs) resulted in a rapid increase in the expression of TRAIL mRNA and cell surface TRAIL protein. Induction of the transdominant repressor of IkappaBalpha dramatically down-regulated surface expression of TRAIL, indicating an essential role for NF-kappaB in the regulation of TRAIL. The induced expression of TRAIL was linked to a c-Rel binding site in the proximal TRAIL promoter at position -256 to -265; mutation of this site or an adjacent kappaB site resulted in a complete loss of the inducibility of the TRAIL promoter. The regulation of TRAIL expression by NF-kappaB may represent a general mechanism that contributes to the control of TRAIL-mediated apoptosis in T lymphocytes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Antibodies, Monoclonal / pharmacology
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Apoptosis Regulatory Proteins
  • CD28 Antigens / immunology
  • CD3 Complex / immunology
  • DNA-Binding Proteins / chemistry
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / physiology*
  • Gene Expression Regulation / drug effects*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • I-kappa B Proteins*
  • Ionomycin / pharmacology
  • Jurkat Cells
  • Membrane Glycoproteins / biosynthesis*
  • Membrane Glycoproteins / genetics
  • Mutagenesis, Site-Directed
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / physiology*
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Phytohemagglutinins / pharmacology
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-rel / metabolism
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • RNA, Neoplasm / biosynthesis
  • RNA, Neoplasm / genetics
  • Recombinant Fusion Proteins / physiology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / metabolism
  • TNF-Related Apoptosis-Inducing Ligand
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transcription, Genetic / drug effects*
  • Transfection
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Apoptosis Regulatory Proteins
  • CD28 Antigens
  • CD3 Complex
  • DNA-Binding Proteins
  • I-kappa B Proteins
  • Membrane Glycoproteins
  • NF-kappa B
  • NFKBIA protein, human
  • Neoplasm Proteins
  • Phytohemagglutinins
  • Proto-Oncogene Proteins c-rel
  • RNA, Messenger
  • RNA, Neoplasm
  • Recombinant Fusion Proteins
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • Tumor Necrosis Factor-alpha
  • NF-KappaB Inhibitor alpha
  • Ionomycin
  • Tetradecanoylphorbol Acetate